Lv5
850 积分 2022-03-31 加入
CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma
1个月前
已完结
Ablation of FAS confers allogeneic CD3– CAR T cells with resistance to rejection by T cells and natural killer cells
4个月前
已完结
Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma
4个月前
已完结
Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma
4个月前
已完结
Shikonin reverses cancer-associated fibroblast-induced gemcitabine resistance in pancreatic cancer cells by suppressing monocarboxylate transporter 4-mediated reverse Warburg effect
6个月前
已完结
Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis
7个月前
已完结
Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis
7个月前
已完结
CAR T cell combination therapies to treat cancer
7个月前
已完结
Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy
10个月前
已完结
Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo
10个月前
已完结
皖公网安备34019202002308
